Newsletter | September 3, 2026

09.03.26 -- How To Match CGT Manufacturing Models To Pipeline Needs With Legend Biotech

SPONSOR

Webinar: Beyond the Starting Material: Building a Path to GMP Manufacturing Success

Cell therapy manufacturing success starts long before the GMP cleanroom. Join experts from New York Blood Center Enterprises’ Comprehensive Cell Solutions (CCS) team to explore how starting material sourcing, collection strategies, process development, and technology transfer shape manufacturing outcomes. Gain practical insights for reducing variability, strengthening process robustness, and preparing cell therapy programs for clinical and commercial manufacturing. Click here to learn more.

FOCUS ON OUTSOURCING

How To Match CGT Manufacturing Models To Pipeline Needs

This opening segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech discussing how early manufacturing decisions shape scalability and commercialization.

Stop Selecting Pharma CDMOs On Cost: A Strategic Playbook

Stop selecting pharma CDMOs on cost alone. Discover a cross-functional supplier selection framework to mitigate long-term manufacturing failures.

How To Evaluate CRO Partnerships Using Proven Data Insights

If your organization is uncertain about what truly separates strong research partnerships from disappointing ones, these data-driven findings can help you improve how you select, evaluate, and manage CRO partnerships.

Late-Phase Process Development Capabilities Are Stronger Than Ever

Late-phase cell therapy programs require process control, automation, and characterization to improve consistency, reduce regulatory risk, and enable commercial-scale manufacturing.

Real-Time Visibility Is Changing Outsourced Gene Therapy Programs

Outsourced gene therapy suffers from fragmented network visibility. Learn how an integrated operating model unifies execution data to speed decision-making.

What To Get Right Early In Subcutaneous Biologics Development

High-concentration biologics can face viscosity and aggregation challenges. Early modeling and targeted testing optimize formulations for stability, manufacturability, and delivery.

SPONSOR

Scaling Innovation Across the Pharmaceutical Lifecycle

The 2026 ISPE Annual Meeting & Expo is more than a learning experience—it's a unique opportunity to connect with professionals from every corner of the pharmaceutical industry. Engage with manufacturers, regulators, suppliers, consultants, and technology innovators, exchange ideas with peers facing similar challenges, and explore the latest products and services in the expansive Expo Hall. Valuable connections and fresh perspectives await at every turn. LEARN MORE. 
 

OUTSOURCING SOLUTIONS

Accelerate Your Next In Vivo CAR-T Program - Lonza

Scale From Tech Transfer To High-Volume Readiness - ElevateBio

Ramp Up Your AAV Production With AAV Platform Technology - Lonza

Apheresis Collection Sites And Capacity - Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises

See How We Bring Biotech Innovation To Life! - 3PBIOVIAN

Fast Track Your Therapy With Our Viral Vector Services - SK pharmteco

Connect With Cell & Gene: